The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial

BMC Neurology

Volumn 7, Issue , 2007, Pages

  Rockwood, Kenneth ^a   Fay, Sherri ^a   Gorman, Mary ^a,b   Carver, Daniel ^a   Graham, Janice E ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b St Martha's Regional Hospital   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; RATING SCALE; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; HOSPITALIZATION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; STATISTICS; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 35448953471     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-7-26     Document Type: Article

References (29)

1. Perras C, Shukla VK, Lessard C, Skidmore B, Bergman H, Gauthier S: Cholinesterase inhibitors for Alzheimer's disease: A systematic review of randomized controlled trials [Technology report no 58] Ottawa: Canadian Consulting Office for Health Technology Assessment 2005
2. Rockwood K, Black SE, Robillard A, Lussier I: Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: A physician survey. Int J Geriatr Psychiatry 2004. 19:954-960. 10.1002/gps.1188 15449367
3. Rockwood K, MacKnight C: Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemioly 2001, 20:51-56. 10.1159/000054761
4. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P: AD2000 Collaborative Group Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 2004, 363:2105-2115. 10.1016/S0140-6736(04)16499-4 15220031
5. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H: Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ 2005, 331:321-327. 1183129 16081444 10.1136/bmj.331.7512.321
6. Kaduszkiewicz H: An innovative approach to involve patients in measuring treatment effects in drug trials. CMAJ 2006, 174:1117-1118. 1421449 16554497
7. Rockwood K. Fay S. Song X. MacKnight C. Gorman M. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: A randomized control trial. CMAJ 2006, 174:1099-1105. 1421447 16554498
8. Burback D, Molnar FJ, St John, P Man-Son-Hing M: Key methodological features of randomized controlled trials of Alzheimer's disease therapy: Minimal clinically important difference, sample size and trial duration. Dement Geriatr Cogn Disord 1999, 10:534-540. 10.1159/000017201 10559571
9. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatr 1984, 141:1356-1364. 6496779
10. Matthews HP, Korbey J, Wilkinson DG, Rowden J: Donepezil in Alzheimer's disease: Eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000, 5:713-720. 10.1002/ 1099-1166(200008)15:8<713::AID-GPS187>3.0.CO;2-I
11. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D: Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003, 60:843-848. 10.1001/ archneur.60.6.843 12810489
12. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ: Alzheimer's Disease Cooperative Study Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003, 289:2819-2826. 10.1001/jama.289.21.2819 12783912
13. Le Bars PL, Kieser M, Itil KZ: A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disordb 2000, 11:230-237. 10.1159/000017242
14. Rockwood K, Graham J, Fay S: Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 2002, 73:500-507. 10.1136/jnnp.73.5.500 12397141
15. Asp E, Cloutier F, Fay S, Cook C, Robertson ML, Fisk J, Wei DW, Rockwood K: Verbal repetition in patients with Alzheimer's disease who receive donepezil. Int J Geriatr Psychiatry 2006, 21:426-31. 10.1002/gps.1486 16676290
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944. 6610841
17. Clarfield AM: Tssessing dementia: the Canadian consensus. Organizing Committee, Canadian Consensus Conference on the Assessment of Dementia. CMAJ 1991, 144:851-853. 1335280 2007235
18. Morris JC: The Clinical Dementia rating (CDR): Current version and scoring rules. Neurology 1993, 43:2412-2414. 8232972
19. Kiresuk TJ, Sherman RE: Goal Attainment Scaling: A general method for evaluating comprehensive community health programs. Community Ment Health J 1968, 4:443-453. 10.1007/BF01530764
20. Schneider LS, Olin JT: Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr 1996, 8:277-88. 10.1017/ S1041610296002645 8994897
21. Folstein MF, Folstein S, McHugh PR, "Mini-Mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975, 12:189-198. 10.1016/ 0022-3956(75)90026-6
22. Lawton MP, Brody EM: Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186. 5349366
23. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell Scale for Depression in Dementia Biol Psychiatry 1988, 23:271-284. 10.1016/ 0006-3223(88)90038-8 3337862
24. Kurlowicz LH, Evans LK, Strumph NE, Maislin G: A psychometric evaluation of the cornell scale for depression in dementia in a frail nursing home population. Am J Geriatr Psychiatry 2002, 10:600-608. 10.1176/ appi.ajgp.10.5.600 12213695
25. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, 1:CD005593. 16437532
26. Quinn J, Moore M, Benson DF, Clark CM, Doody R, Jagust W, Knopman D, Kaye JA: A videotaped CIBIC for demeVtia patients: validity and reliability in a simulated clinical trial. Neurology 2002, 58:433-437. 11839844
27. Joffres C, Graham JE, Rockwood K: A Qualitative Analysis of The Clinician Interview-Based Impression of Change (Plus): Methodological Issues and Implications for Clinical Research. Int Psychogeriatr 2000, 12:403-413. 10.1017/S1041610200006505 11081960
28. Joffres C, Bucks RS, Haworth J, Wilcock GK, Rockwood K: Patterns of clinically detectable treatment effects with galantamine: A qualitative analysis. Demen Geriatric Cog Disord 2003, 15:26-33. 10.1159/000066673
29. Hogan DB: Donepezil for severe Alzheimer's disease. Lancet 2006, 367(9516):1031-2. 10.1016/S0140-6736(06)68395-5 16581404